- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02331446
The Effect of Different Volumes of Physical Exercise on the Immune System (ProAFIM)
Dose-response Effects of Different Volumes of Structured Exercise in the Inflammatory and Oxidative Stress Parameters in Postmenopausal Women: a Randomized Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The protocol will consist of an intervention based on concurrent training, for previously sedentary post-menopausal women divided on four groups: 1) control group; 2) 90 minutes of physical training per week; 3) 150 minutes of training per week; 4) 210 minutes of training per week.
The control group will be oriented to maintain their normal activity and habits and will not receive the intervention. The group of 90 minutes per week will do three sessions of 30 minutes per week of concurrent training, which consists on 15 minutes of aerobic exercise and 15 minutes of strength training. The group of 150 minutes will do three sessions of 50 minutes per week, which consists on 25 minutes of aerobic exercise and 25 minutes of strength training. The group pf 210 minutes per week will do three sessions of 70 minutes per week, which consists on 35 minutes of aerobic exercise and 35 minutes of strength training.
The aerobic exercise will be performed on cycle-ergometers and the subjects will exercise between the levels 14 and 15 of Borg's scale of perceived exertion. The strength training will be performed on weight machines by a linear periodization, which will consist on a week of adaptation (series of 10 to 12 submaximal repetitions), next three weeks with series of 12 to 14 maximal repetitions, weeks five to eight with series of 10 to 12 maximal repetitions, weeks nine to twelve with series of eight to 10 maximal repetitions. Al participants will do the maximum number of series of strength training that the time permits.
The blood samples will be collected at the beginning of the study (week zero), at the middle (week six) and at the end (week 12). The subjects will fill a 24-hour food recall (to control the food intake) and the commuting and leisure sections of the International Physical Activity Questionnaire (to control the physical activity practiced out of the intervention).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women have to be in the postmenopausal period, without physical disorders.
Exclusion Criteria:
- Women who answer positively to, at least, one of the issues of the PAR-Q instrument;
- Women with diabetes and/or cancer history;
- Women who underwent oophorectomy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Control
The control group will be oriented to maintain their normal activity and habits and will not receive the intervention.
|
|
|
Experimental: 90 minutes per week
The group of 90 minutes per week will do three sessions of 30 minutes per week of concurrent training, which consists on 15 minutes of aerobic exercise and 15 minutes of strength training.
|
|
|
Experimental: 150 minutes per week
The group of 150 minutes will do three sessions of 50 minutes per week, which consists on 25 minutes of aerobic exercise and 25 minutes of strength training.
|
|
|
Experimental: 210 minutes per week
The group pf 210 minutes per week will do three sessions of 70 minutes per week, which consists on 35 minutes of aerobic exercise and 35 minutes of strength training.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in Interleukin-6
Time Frame: Weeks 0, 6 and 12
|
Weeks 0, 6 and 12
|
|
Change in Adenosine Deaminase Activity
Time Frame: Weeks 0, 6 and 12
|
Weeks 0, 6 and 12
|
|
Change in Butyrylcholinesterase Activity
Time Frame: Weeks 0, 6 and 12
|
Weeks 0, 6 and 12
|
|
Change in Thiobarbituric Acid Reactive Substances
Time Frame: Weeks 0, 6 and 12
|
Weeks 0, 6 and 12
|
|
Change in Total Thiol Content
Time Frame: Weeks 0, 6 and 12
|
Weeks 0, 6 and 12
|
|
Change in Glutathione Peroxidase Activity
Time Frame: Weeks 0, 6 and 12
|
Weeks 0, 6 and 12
|
|
Change in Superoxide Dismutase Activity
Time Frame: Weeks 0, 6 and 12
|
Weeks 0, 6 and 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Performance in the Six-minute Walk Test
Time Frame: Weeks 0 and 12
|
Weeks 0 and 12
|
|
|
Change in Handgrip Strength
Time Frame: Weeks 0 and 12
|
Measured using a handgrip dynamometer and quantified in kilogram-force
|
Weeks 0 and 12
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Body Mass Index
Time Frame: Weeks 0 and 12
|
Weeks 0 and 12
|
|
|
Change in Minutes Per Week of Physical Activity Out of Intervention
Time Frame: Week 0 and 12
|
Measured by the commuting and leisure sections of the International Physical Activity Questionnaire
|
Week 0 and 12
|
|
Change in Calories Intake
Time Frame: Weeks 0 and 12
|
Measured by a 24-hour food recall and quantified in calories
|
Weeks 0 and 12
|
|
Educational Level
Time Frame: Week 0
|
Measured by a questionnaire and quantified categorically in: Incomplete primary school; Primary school; Incomplete high school; High school; Incomplete higher education; Higher education.
The number of baseline participants is not consistent with number provided in the Participant Flow module because two of the beginning participants did not arrived on the first data collection.
Due to this, these participants (one of the 90 min/week, and other of the 150 min/week group) were lost to follow-up before the baseline data collection.
|
Week 0
|
|
Household Income
Time Frame: Week 0
|
Measured by a questionnaire and quantified by the income of all persons in the participant's home.
The number of baseline participants is not consistent with number provided in the Participant Flow module because two of the beginning participants did not arrived on the first data collection.
Due to this, these participants (one of the 90 min/week, and other of the 150 min/week group) were lost to follow-up before the baseline data collection.
|
Week 0
|
|
Age
Time Frame: Week 0
|
The number of baseline participants is not consistent with number provided in the Participant Flow module because two of the beginning participants did not arrived on the first data collection.
Due to this, these participants (one of the 90 min/week, and other of the 150 min/week group) were lost to follow-up before the baseline data collection.
|
Week 0
|
|
Chronic Use of Medication
Time Frame: Week 0
|
Measured by a questionnaire and quantified categorically in: No; Yes.
This variable refers to a chronic use of any medication.
The number of baseline participants is not consistent with number provided in the Participant Flow module because two of the beginning participants did not arrived on the first data collection.
Due to this, these participants (one of the 90 min/week, and other of the 150 min/week group) were lost to follow-up before the baseline data collection.
|
Week 0
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Matheus P Freitas, Federal University of Pelotas
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 27371214.4.0000.5313
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Immune System Diseases
-
University of HelsinkiTampere UniversityCompletedImmune System DisordersFinland
-
Kadmon, a Sanofi CompanyCompletedImmune System Disorder (Healthy Volunteer)United States
-
Kadmon, a Sanofi CompanyCompletedImmune System Disorder (Healthy Volunteer)United States
-
Kadmon, a Sanofi CompanyCompletedImmune System Disorder (Healthy Volunteer)United States
-
SanofiTerminatedImmune System DisorderUnited States, Spain
-
National Heart, Lung, and Blood Institute (NHLBI)National Cancer Institute (NCI); Blood and Marrow Transplant Clinical Trials...CompletedGraft vs Host Disease | Immune System DisordersUnited States
-
University Hospital, LimogesCompleted
-
Shanghai Henlius BiotechCompleted
-
University Hospital, LilleLaboratoire français de Fractionnement et de BiotechnologiesCompleted
-
Grit BiotechnologyAffiliated Hospital of Nantong UniversityRecruiting
Clinical Trials on Physical exercise intervention
-
Fundacion Miguel ServetUniversidad Pública de Navarra; Complejo Hospitalario de NavarraCompletedFrailty | Disability Physical | Hospital Acquired ConditionSpain
-
Tigers Running ClubCompletedBreast Cancer | Cancer SurvivorsSpain
-
Brigham and Women's HospitalUniversity of California, Davis; University of South Carolina; Society and Health... and other collaboratorsRecruitingBehavioral and Psychological Symptoms of Dementia (BPSD)Thailand
-
University of BaselCompletedPhysical InactivitySwitzerland
-
Asociación Española contra el CáncerCompletedCancer Patients in Different StagesSpain
-
VA Office of Research and DevelopmentActive, not recruiting
-
Institute VerbeetenCZ Fonds; Verbeeten Fonds; Stichting Fight CancerRecruiting
-
Oslo University HospitalThe Research Council of Norway; St. Olavs HospitalActive, not recruitingStage I Breast Cancer | Stage II Breast Cancer | DCIS Grade 3 | LCIS, Lobular Carcinoma in SituNorway
-
University of California, IrvineMassachusetts General Hospital; University of Missouri-ColumbiaCompletedControl Condition | Physical Exercise ConditionUnited States
-
Mgr. Eliška VrátnáVladimíra Fejfarová, MD, PhD; prof. Ing. Václav Bunc, CScUnknownPrevention of Diabetic FootCzechia